Acute Porphyria Drug Database

S01EE05 - Tafluprost
Not porphyrinogenic
NP

Rationale
Administered locally in the eye and systemic exposure is insignificant.
Chemical description
Fluorinated analog of prostaglandin F2-alpha.
Therapeutic characteristics
Tafluprost eye drops reduce elevated intraocular pressure in open angle glaucoma and ocular hypertension.
Hepatic exposure
Mean plasma tafluprost acid concentrations were below the limit of quantification of the bioanalytical assay (10 pg/mL) and hepatic exposure is therefore insignificant (SPC).
Metabolism and pharmakokinetics
Tafluprost is a prodrug and is hydrolyzed to the pharmacologically active metabolite, tafluprost acid. Tafluprost acid is further metabolized by glucuronidation and beta-oxidation. CYP450 enzymes are not involved in the metabolism.

References

  1. Summary of Product Characteristics
  2. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Saflutan. #2934

Similar drugs
Explore alternative drugs in similar therapeutic classes S01E / S01EE or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙